Dr. Fowler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030- Is this information wrong?
Education & Training
- MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2004 - 2007
- University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2001 - 2004
- University of Texas Medical Branch School of MedicineClass of 2001
- University of HoustonBS (Honors), Biology
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2007 - 2025
- OK State Medical License 2020 - 2021
- DC State Medical License 2004 - 2008
Awards, Honors, & Recognition
- Patient's Choice Award Registry, 2015-2019
- Waun Ki Hong Award in Team Science MD Anderson Cancer Center, 2018
- Most Compassionate Doctor Award Registry, 2009, 2011-2018
- Join now to see all
Clinical Trials
- Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma Start of enrollment: 2004 Jun 29
- Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma Start of enrollment: 2006 Nov 01
- Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients Start of enrollment: 1998 Mar 16
- Join now to see all
Publications & Presentations
PubMed
- Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.Dickinson, M., Martinez-Lopez, J., Jousseaume, E., Yang, H., Chai, X., Xiang, C., Wang, T., Zhang, J., Ramos, R., Schuster, S., Fowler, N.> ;Leukemia & Lymphoma. 2024 Mar 1
- Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 s...Max J Gordon, Lei Feng, Paolo Strati, Hun Ju Lee, Fredrick B Hagemeister, Jason R Westin, Felipe Samaniego, Mario L Marques-Piubelli, Francisco Vega Vazquez, Edwin R P...> ;Cancer. 2024 Mar 15
- 1 citationsImmune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma.Preetesh Jain, Krystle Nomie, Nikita Kotlov, VitaIy Segodin, Holly Hill, Chi Young Ok, Ahmed Fetooh, Rashmi Kanagal-Shamanna, Francisco Vega, Alexander Bagaev, Nathan ...> ;Blood Cancer Journal. 2023 Oct 12
- Join now to see all
Journal Articles
- Venetoclax, Bendamustine, and Rituximab in Patients with Relapsed or Refractory NHL: A Phase 1b Dose-Finding StudyN Fowler, E Reid, L J Nastoupil, Annals of Oncology
Abstracts/Posters
- Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCLNathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed p...2019 ASCO Annual Meeting - 6/1/2019
- Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- BostonGene and Sylvester Comprehensive Cancer Center at the University of Miami Announce CollaborationMay 23rd, 2023
- BostonGene Announces Publication in Cell Reports Revealing Spatial Heterogeneity in the Tumor Microenvironment of Multiregional Clear Cell Renal Cell Carcinoma BiopsiesOctober 4th, 2022
- BostonGene Showcases Lifesaving Cancer Diagnostic and Treatment Recommendation Test at the 81st Annual Meeting of the Japanese Cancer AssociationSeptember 21st, 2022
- Join now to see all
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: